Second phase of the trial with autologous cord blood in autism

According to the Duke Center for Autism, “previous research has shown that cord blood cells can help reduce inflammation and signal cells to help repair damaged brain areas. The goal of this study was to investigate whether similar success will be shown in children with ASD.”

“But the study is blinded, so no one knows what their child received or what order,” said Kurtzberg.

This is Duke’s second phase of this trial and these results won’t be analyzed until next fall; however, the trial’s first phase, which is already complete, showed promising results for the children with autism who participated in the study.

“And we found that about 70 percent of the children improved getting their own cord blood,” said Kurtzberg. If this second trial also shows that cord blood is beneficial, Duke will work with the FDA to expedite approval of this treatment for all children.

One of the families that participe in this study said that her family is grateful and humbled by being chosen to take part in this medical trial, and they hope the results will one day be able to help all families dealing with autism.

ORIGINAL SOURCE nbcdfw.com (July 2018)

LINK TO CLINICAL TRIAL clinicaltrials.gov/ct2/show/NCT03327467